Literature DB >> 25912468

The Framingham cardiovascular risk score in multiple sclerosis.

M Moccia1, R Lanzillo1, R Palladino2,3, G T Maniscalco1,4, A De Rosa1, C Russo1, M Massarelli1, A Carotenuto1, E Postiglione1, O Caporale2, M Triassi2, V Brescia Morra1.   

Abstract

BACKGROUND AND
PURPOSE: Cardiovascular risk factors can increase the risk of multiple sclerosis (MS) and modify its course. However, such factors possibly interact, determining a global cardiovascular risk. Our aim was to compare the global cardiovascular risk of subjects with and without MS with the simplified 10-year Framingham General Cardiovascular Disease Risk Score (FR) and to evaluate its importance on MS-related outcomes.
METHODS: Age, gender, smoking status, body mass index, systolic blood pressure, type II diabetes and use of antihypertensive medications were recorded in subjects with and without MS to estimate the FR, an individualized percentage risk score estimating the 10-year likelihood of cardiovascular events.
RESULTS: In total, 265 MS subjects were identified with 530 matched controls. A t test showed similar FR in cases and controls (P = 0.212). Secondary progressive MS presented significantly higher FR compared to relapsing-remitting MS (P < 0.001). Linear regression analysis showed a direct relationship between FR and Expanded Disability Status Scale (P < 0.001) and MS Severity Scale (P < 0.001).
CONCLUSION: The FR, evaluating the global cardiovascular health by the interaction amongst different risk factors, relates to MS disability, severity and course.
© 2015 EAN.

Entities:  

Keywords:  Framingham; cardiovascular; comorbidities; multiple sclerosis

Mesh:

Year:  2015        PMID: 25912468     DOI: 10.1111/ene.12720

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  13 in total

1.  Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS.

Authors:  Amber Salter; Tuula Tyry; Guoqiao Wang; Robert J Fox; Gary Cutter; Ruth Ann Marrie
Journal:  Neurol Clin Pract       Date:  2016-10

2.  Cardiovascular profile improvement during Natalizumab treatment.

Authors:  Marcello Moccia; Roberto Albero; Roberta Lanzillo; Francesco Saccà; Anna De Rosa; Cinzia Valeria Russo; Antonio Carotenuto; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  Metab Brain Dis       Date:  2017-12-18       Impact factor: 3.584

Review 3.  Comorbidity in multiple sclerosis: implications for patient care.

Authors:  Ruth Ann Marrie
Journal:  Nat Rev Neurol       Date:  2017-03-17       Impact factor: 42.937

4.  Fractional anisotropy of white matter, disability and blood iron parameters in multiple sclerosis.

Authors:  Estelle Herbert; Penelope Engel-Hills; Coenraad Hattingh; Jean-Paul Fouche; Martin Kidd; Christine Lochner; Maritha J Kotze; Susan J van Rensburg
Journal:  Metab Brain Dis       Date:  2018-02-02       Impact factor: 3.584

5.  Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.

Authors:  Hanne Marie Bøe Lunde; Jörg Assmus; Kjell-Morten Myhr; Lars Bø; Nina Grytten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-04-01       Impact factor: 10.154

6.  Effects of Systolic Blood Pressure on Brain Integrity in Multiple Sclerosis.

Authors:  Daiana E Dossi; Hernán Chaves; Evelyn S Heck; Sofía Rodriguez Murúa; Fernando Ventrice; Rohit Bakshi; Francisco J Quintana; Jorge Correale; Mauricio F Farez
Journal:  Front Neurol       Date:  2018-06-25       Impact factor: 4.003

7.  Gene expression in oligodendrocytes during remyelination reveals cholesterol homeostasis as a therapeutic target in multiple sclerosis.

Authors:  Rhonda R Voskuhl; Noriko Itoh; Alessia Tassoni; Macy Akiyo Matsukawa; Emily Ren; Vincent Tse; Ellis Jang; Timothy Takazo Suen; Yuichiro Itoh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-30       Impact factor: 11.205

8.  The Molecular Aspects of Disturbed Platelet Activation through ADP/P2Y12 Pathway in Multiple Sclerosis.

Authors:  Angela Dziedzic; Elzbieta Miller; Joanna Saluk-Bijak; Marta Niwald; Michal Bijak
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

9.  Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.

Authors:  Tingting Zhang; Helen Tremlett; Stella Leung; Feng Zhu; Elaine Kingwell; John D Fisk; Virender Bhan; Trudy L Campbell; Karen Stadnyk; B Nancy Yu; Ruth Ann Marrie
Journal:  Neurology       Date:  2016-03-04       Impact factor: 9.910

10.  Neuroprotective effects of exercise in people with progressive multiple sclerosis (Exercise PRO-MS): study protocol of a phase II trial.

Authors:  A S Gravesteijn; H Beckerman; B A de Jong; H E Hulst; V de Groot
Journal:  BMC Neurol       Date:  2020-05-11       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.